KOSDAQElectronic Components263690

Drgem

₩4,955▲ 0.10%2026-11-18 close
Market Cap
₩56.1B
Turnover
₩56,718,870
Volume
10K
Shares out.
11.3M
PER
4.4×
PBR
0.5×
EPS
₩1,141
Dividend Yield
3.57%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩178 per share · Prices as of the 2026-11-18 close

01

Report overview

Drgem: Operating profit rebounds, net profit trend mixed

Drgem's operating profit in the third quarter of 2026 rose 190.6% year on year, showing a clear recovery at the operating level, while net profit attributable to controlling shareholders has fallen for two consecutive quarters since its first-quarter 2026 peak.

  1. 1

    Third-quarter 2026 revenue reached KRW 42.8 billion, up 43.3% from the prior quarter, and operating profit reached KRW 6.42 billion, up 190.6% year on year.

  2. 2

    Net profit attributable to controlling shareholders was KRW 2.16 billion in the same quarter, down 39.7% from the prior quarter but up 8.0% year on year.

  3. 3

    The annual operating margin fell from 15.4% in 2022 to 8.9% in 2023 and has stayed in the 8% range through 2025, at 8.8%.

  4. 4

    Net profit attributable to controlling shareholders fell 33.2% to KRW 6.78 billion in 2025, while the four quarters from Q4 2025 to Q3 2026 total KRW 12.4 billion.

  5. 5

    The debt-to-equity ratio fell from 72.1% in 2022 to 32.4% in 2025, and in August 2026 the company said a KRW 19.3 billion supply contract in Turkey would be reflected in results from the third quarter.

02

Business structure

Drgem designs, develops, manufactures and sells diagnostic X-ray imaging systems used by hospitals and clinics. In the first quarter of 2026, General DR accounted for 78.4% of revenue, Mobile DR for 7.0%, and other products and parts for 14.6%, according to the company.

General DR, the core product line, drove revenue growth in that quarter, and the company said higher sales of other products and parts also helped profitability. Exports account for a large share of sales, and one business report article reported that 86% of revenue comes from overseas and 14% from domestic sales.

The same article said the sales network is not concentrated in a few customers. Its markets are split between established regions such as North America, Europe and the Middle East and emerging markets including South America, Africa and Asia.

The product line is expanding to include the AP System premium digital radiography system, the RAYMO mobile X-ray system, the AI-based C-arm PROVUE under development, and the DS30 and DS20 ultrasound units. The company said RAYMO received FDA clearance and CE certification in the first half of 2026.

Management is pursuing a strategy of moving beyond equipment supply toward a digital medical imaging solutions business built on its in-house imaging software. It cites product competitiveness, quality and cost reduction as the core of its competitive position.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩24.4B₩2.2B9.1%
2025Q4₩27.9B₩2.2B7.7%
2026Q1₩27.3B₩2.7B10.0%
2026Q2₩29.9B₩3.5B11.7%
2026Q3₩42.8B₩6.4B15.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩110.2B₩17B₩14.4B15.4%19.5%72.1%
2023₩112.9B₩10.1B₩9.2B8.9%11.6%61.9%
2024₩104B₩8.9B₩10.1B8.5%11.7%40.8%
2025₩102.7B₩9B₩6.8B8.8%7.4%32.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue rose from KRW 110.2 billion in 2022 to KRW 112.9 billion in 2023, up 2.5%, before falling 7.9% to KRW 104 billion in 2024 and 1.2% to KRW 102.7 billion in 2025, a two-year decline from 2024 through 2025. Within 2022 to 2025, 2023 was the largest year and 2025 the smallest.

Operating profit fell from KRW 17 billion in 2022 to KRW 10.1 billion in 2023, down 40.6%, dipped to KRW 8.85 billion in 2024, down 12.1%, and recovered slightly to KRW 9.03 billion in 2025, up 2.0%.

The operating margin dropped from 15.4% in 2022 to 8.9% in 2023 and then stayed in the 8% range, at 8.5% in 2024 and 8.8% in 2025. In 2023 revenue grew 2.5% while operating profit fell 40.6%, so the margin decline was concentrated in that year.

Net profit attributable to controlling shareholders fell from KRW 14.4 billion in 2022 to KRW 9.19 billion in 2023, down 36.1%, recovered to KRW 10.1 billion in 2024, up 10.4%, and then declined to KRW 6.78 billion in 2025, down 33.2%.

The net profit figures including non-controlling interests are, for each year from 2022 to 2025, the same amounts as net profit attributable to controlling shareholders.

At the end of 2025, total equity was KRW 92.1 billion and total liabilities were KRW 29.9 billion, while operating cash flow was KRW 7.35 billion in 2022, KRW 15 billion in 2023, KRW 3.68 billion in 2024 and KRW 11.6 billion in 2025, with wide swings between years.

Quarterly revenue rose from KRW 24.4 billion in the third quarter of 2025 to KRW 27.9 billion in the fourth quarter, up 14.5%, dipped 2.0% to KRW 27.3 billion in the first quarter of 2026, and then grew to KRW 29.9 billion in the second quarter, up 9.4%, and KRW 42.8 billion in the third quarter, up 43.3%.

Operating profit bottomed at KRW 2.16 billion in the fourth quarter of 2025 and then rose to KRW 2.74 billion, KRW 3.5 billion and KRW 6.42 billion over the next three quarters.

Over the same period, net profit attributable to controlling shareholders peaked at KRW 3.98 billion in the first quarter of 2026 and then fell to KRW 3.58 billion and KRW 2.16 billion.

Third-quarter operating profit grew 190.6% year on year against 8.0% growth in net profit, a wide gap between the operating and net profit lines.

The company said in August 2026 that a KRW 19.3 billion medical equipment supply contract in Turkey would be reflected from the third quarter, a timing that coincides with the third-quarter revenue increase.

The four quarters from Q4 2025 to Q3 2026 total KRW 12.4 billion in net profit attributable to controlling shareholders, below the KRW 14.4 billion recorded for 2022 alone.

05

Industry analysis

According to the company, demand for Drgem's equipment comes from hospitals and clinics converting to digital X-ray. In its first-quarter 2026 results release, the company said demand for digital X-ray conversion is expanding, centered on South America and Africa.

The same release said growth in the digital radiography (DR) market lifted sales of its core General DR product. The company also said order backlogs in established markets such as North America, Europe and the Middle East remain stable.

At the same time, it pointed to global economic uncertainty and geopolitical risk in the Middle East. Because regional demand shifts pass quickly into revenue from a sales base weighted toward exports, regional risk could have a large effect, which is the starting point for reading the industry picture.

On competition, the company emphasized its in-house imaging software, quality competitiveness and cost reduction. In March 2026 the company said its AI noise-reduction technology could deliver similar image quality at a radiation dose roughly 70% lower than before.

At RSNA 2025 it unveiled the RAYMO mobile DR system and the RadTrainer training platform. Because the industry view currently rests mainly on company statements, it still needs to be checked against external market data.

06

Outlook

In its August 2026 release, the company said it expects earnings growth to continue in the second half of the year. The KRW 19.3 billion supply contract in Turkey, which the company said would be reflected from the third quarter, was presented as a key variable for second-half revenue.

RAYMO received FDA clearance and CE certification in the first half of 2026 and was positioned as a means to widen overseas market share.

The AI-based C-arm PROVUE, which the company said can cut radiation exposure by about 70%, is targeted for commercialization in the second half of 2026, according to a March 2026 company statement.

The company said it plans to start its ultrasound business using a channel of more than 300 global partners across more than 130 countries. At KIMES 2026 it showed the DS30 and DS20 ultrasound units alongside its X-ray lineup, framing a one-stop imaging diagnostics offering.

Over the medium term, the company plans to expand into industrial X-ray equipment, other medical devices and new software. It said emerging-market efforts will be strengthened, centered on South America and Asia.

Whether these plans convert into revenue will be checked through the PROVUE commercial launch and the start of the ultrasound business.

The 2026 annual report, the next periodic filing, will be the first to include fourth-quarter 2026 results, so operating margin and the size of the Turkey contract's contribution will be checked there.

07

Valuation

PER
4.4×
PBR
0.5×
ROE
13.2%
EPS
₩1,141
BPS
₩9,148
Dividend per share
₩178

The current share price sits well below book value, with the price-to-book ratio in a range far under 1 times. The market capitalization is below total equity at the end of 2025, a factual comparison rather than a valuation call.

The price-to-earnings ratio should be read alongside net profit attributable to controlling shareholders over the most recent four quarters. Whether that total recovers to the 2022 annual level is the point to check when reading the ratio.

Annual net profit attributable to controlling shareholders fell from 2022 to 2025, while operating profit has been recovering through 2026, so the earnings-based reading is mixed. The March 2026 annual general meeting approved a cash dividend, and the dividend yield moves with the share price.

The debt-to-equity ratio fell from 72.1% in 2022 to 32.4% in 2025. The valuation picture depends on how far the operating profit recovery carries through to net profit attributable to controlling shareholders.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Overseas digital conversion demand

In its first-quarter 2026 results release, the company said demand for digital X-ray conversion is rising, centered on South America and Africa. The same release credited higher overseas orders and strong General DR sales for revenue growth. It also said order backlogs in North America, Europe and the Middle East remain stable.

Operating profit recovery

Third-quarter 2026 operating profit reached KRW 6.42 billion, up 190.6% year on year, and has risen for three consecutive quarters from the fourth-quarter 2025 low. The company said in August 2026 that expanded overseas sales and a better product mix contributed to profitability. Whether the margin gain continues in later quarters is the point to check for this factor.

Expanding product pipeline

The AI low-dose C-arm PROVUE is targeted for commercial launch in the second half of 2026, and the ultrasound business is planned to start through a channel of more than 300 partners in over 130 countries. The new products are presented as tools for widening overseas market share.

09

Bear factors

Slowing net profit to controlling shareholders

Net profit attributable to controlling shareholders fell 33.2% to KRW 6.78 billion in 2025. After peaking at KRW 3.98 billion in the first quarter of 2026, it declined to KRW 3.58 billion and then KRW 2.16 billion over the next two quarters. Third-quarter operating profit grew 190.6%, but net profit growth was only 8.0%.

Margins below the 2022 level

The operating margin fell from 15.4% in 2022 to 8.9% in 2023 and has stayed in the 8% range, at 8.8% in 2025. Revenue was KRW 102.7 billion in 2025. The four quarters from Q4 2025 to Q3 2026 total KRW 12.4 billion in net profit attributable to controlling shareholders, below the 2022 annual figure of KRW 14.4 billion.

Dependence on large contracts and regional concentration

Third-quarter 2026 revenue rose 43.3% from the prior quarter, the same quarter in which the company said the KRW 19.3 billion Turkey contract would be reflected. A business report article reported that 86% of revenue comes from exports, which makes the business sensitive to regional demand and geopolitical risk. Large one-off contracts also tend to widen quarter-to-quarter revenue swings.

10

Risk factors

Regional political and economic risk

In its first-quarter 2026 explanation, the company pointed to global economic uncertainty and geopolitical risk in the Middle East. With a sales base weighted toward exports, a shift in demand or order timing in a particular region could widen quarterly revenue swings.

The stable order backlog described for North America, Europe and the Middle East coexists with these regional risks.

New product commercialization timing

PROVUE is under development with a second-half 2026 commercialization target, and in March 2026 the company projected technology completion and market entry for the second half of that year. The ultrasound business and software expansion also still need to show results after the second half of 2026. Any delay would push back the timing of the medium-term growth plan.

Earnings volatility and margin sustainability

Net profit attributable to controlling shareholders fell to KRW 6.78 billion in 2025, and quarterly net profit has declined for two straight quarters since its first-quarter 2026 peak. Operating profit gains have not carried through to net profit in the latest quarter.

Since 2023 the operating margin has stayed in the 8% range, so how long the recent margin recovery lasts is the key question.

11

What to watch next

  1. End of December 2026

    Whether the second-half 2026 commercialization target for PROVUE and the planned start of the ultrasound business are carried out. Whether these translate into actual sales will shape how the overseas product mix and operating margin are read.

  2. March 2027

    Filing of the 2026 annual report. It will be the first periodic filing to include fourth-quarter 2026 results and full-year operating margin and debt ratio, and the annual dividend decision is made at the general shareholders' meeting, as the March 2026 meeting did with a cash dividend.

  3. Around mid-May 2027

    The first-quarter 2027 quarterly report. It is the checkpoint for whether the third-quarter 2026 revenue jump carries into later quarters and whether net profit attributable to controlling shareholders follows the operating profit recovery.

12

Overall view

Drgem's third-quarter 2026 revenue of KRW 42.8 billion and operating profit of KRW 6.42 billion have lifted quarterly earnings to their largest levels in the period shown. On an annual basis, revenue has fallen for two straight years since its 2023 peak, and the operating margin has stayed in the 8% range.

Net profit attributable to controlling shareholders fell 33.2% to KRW 6.78 billion in 2025.

Operating profit has risen for three consecutive quarters in 2026, but net profit attributable to controlling shareholders has declined for two straight quarters since its first-quarter peak, so the operating and net profit lines are moving differently.

Bullish factors include stronger overseas demand for DR systems, the product expansion across RAYMO, PROVUE and ultrasound, and the lower debt-to-equity ratio.

Bearish factors include the annual earnings decline, the timing of the third-quarter revenue jump relative to a large contract, and regional risk in the Middle East. The next checkpoints are the 2026 annual report, the PROVUE commercialization target and the first-quarter 2027 report.

This report does not include a buy or sell opinion or a target price, and its figures are based on DART periodic filings and company announcements.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. vegannews.co.kr
  2. etnews.com
  3. press.reporternside.com
  4. m.news.nate.com
  5. sportpeopletimes.com
  6. kcenews.kr
  7. m.news.nate.com
  8. drgemhealthcare.com
  9. google.com
  10. investing.com
  11. biotimes.co.kr
  12. rapportian.com
  13. kcenews.kr
  14. job.gg.go.kr
  15. businessreport.kr
  16. kairnews.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis